Username:
Password:
Forgot Password?
Remember me
Decade: 2010-2010 2000-2009 1990-1999 1980-1989 1970-1979
Year: 2009 2008 2007 2006 2005 2004 2003 2002 2001 2000
Issues: Vol. 104 No. 12 December 15, 2009 p.1607-1764 Vol. 104 No. 11 December 1, 2009 p.1457-1606 Vol. 104 No. 10 November 16, 2009 p.1E-62E-Supplement Vol. 104 No. 10 November 15, 2009 p.1317-1456 Vol. 104 No. 9 November 1, 2009 p.1165-1316 Vol. 104 No. 8 October 15, 2009 p.1013-1164 Vol. 104 No. 7 October 1, 2009 p.873-1012 Vol. 104 No. 6 September 21, 2009 p.1D-244D-Supplement Vol. 104 No. 6 September 15, 2009 p.745-872 Vol. 104 No. 5 September 7, 2009 p.1C-64C-Supplement Vol. 104 No. 5 September 1, 2009 p.619-744 Vol. 104 No. 4 August 15, 2009 p.459-618 Vol. 104 No. 3 August 1, 2009 p.299-458 Vol. 104 No. 2 July 15, 2009 p.151-298 Vol. 104 No. 1 July 1, 2009 p.1-150 Vol. 103 No. 12 June 15, 2009 p.1629-1776 Vol. 103 No. 11 June 1, 2009 p.1481-1628 Vol. 103 No. 10 May 15, 2009 p.1333-1480 Vol. 103 No. 9 May 1, 2009 p.1183-1332 Vol. 103 No. 9 April 22, 2009 p.1B-132B-Supplement Vol. 103 No. 8 April 15, 2009 p.1045-1182 Vol. 103 No. 7 April 1, 2009 p.897-1044 Vol. 103 No. 6 March 15, 2009 p.755-896 Vol. 103 No. 5 March 1, 2009 p.577-754 Vol. 103 No. 4 February 15, 2009 p.437-576 Vol. 103 No. 3 February 2, 2009 p.1A-60A-Supplement Vol. 103 No. 3 February 1, 2009 p.295-436 Vol. 103 No. 2 January 15, 2009 p.149-294 Vol. 103 No. 1 January 1, 2009 p.1-148
High-Density Lipoprotein as a Therapeutic Target: The Next Frontier in Coronary Arterty Disease Risk Reduction
Edited by Michael H. Davidson MD
This supplement was supported by by an independent educational grant from Roche Pharmaceuticals
Search Within This Issue
12 Articles:
High-Density Lipoprotein as a Therapeutic Target: The Next Frontier in Coronary Artery Disease Risk Reduction
The authors who contributed to this publication have disclosed the following industry relationships:
It is well established that elevated levels of low-density lipoprotein (LDL) cholesterol and reduced levels of high-density lipoprotein (HDL) cholesterol are both independently predictive of increased...
It is well established that low high-density lipoprotein (HDL) cholesterol is a risk factor for coronary artery disease (CAD). Growing evidence from epidemiologic as well as intervention studies have ...
Inhibition of the cholesteryl ester transfer protein (CETP), a plasma protein that normally transfers cholesterol from the protective high-density lipoprotein (HDL) fraction to the atherogenic low-den...
Increasing interest has focused on the potential clinical utility of therapies that promote the biologic activity of high-density lipoprotein (HDL). Arterial wall imaging has been used in clinical tri...
The risk for coronary artery disease (CAD) is inversely correlated with high-density lipoprotein (HDL) cholesterol plasma levels. These plasma HDL cholesterol levels are influenced by the activity of ...
Inhibitors of cholesterol ester transfer protein (CETP) have the capacity to increase plasma high-density lipoprotein cholesterol to unprecedented levels. Still, hopes that CETP inhibition could reduc...
Cholesterol ester transfer protein (CETP) deficiency or inhibition results in dramatic elevations of high-density lipoprotein (HDL) levels, but there has been concern that HDL might be dysfunctional i...
Despite contemporary therapies for acute coronary syndrome (ACS), rates of morbidity and mortality remain high. Low levels of high-density lipoprotein (HDL) cholesterol are common among patients with ...
As the significance of treating coronary artery disease (CAD) remains a high priority in reducing morbidity and mortality worldwide, newer treatment strategies continue to evolve. The efficacy of stat...
